Hepatocellular Carcinoma Database Maps Treatment Patterns in Spain
A specialized tumor registry in Spain is mapping real-world treatment patterns and survival outcomes for more than 800 patients living with hepatocellular carcinoma, according to a report by Infosalus. Managed by the Digestive Tumors Treatment Group, the RETUD tumor registry provides specialists with observational data regarding how patients respond to specific therapies outside of clinical trial settings.
Registry Data Details Advanced Therapy Outcomes
One study, led by Hospital Universitario Marqués de Valdecilla medical oncologist Carlos López, evaluated the combination of atezolizumab and bevacizumab as a first-line systemic therapy for advanced hepatocellular carcinoma.
The analysis examined 247 patients treated with this specific drug combination over a three-year period in Spain. Researchers recorded a progression-free survival rate of 10.3 months and an overall survival rate of 14 months from the start of treatment. The therapy also achieved initial tumor control or a clinical response in a substantial portion of the cohort.
Poorer liver function and macrovascular invasion emerged as negative prognostic indicators, correlating with reduced progression-free survival and overall survival. Fernando Rivera, president of the Digestive Tumors Treatment Group and head of service at the Hospital Marqués de Valdecilla, stated that the database supplies clinicians with practical information to select the most appropriate treatments for individual patient profiles.
Preserving Functional Status for Subsequent Therapies
A second study, led by Hospital Universitario de Burgos medical oncologist Ana María López, examined treatment sequences administered after initial immunotherapy failure. The registry data revealed that tyrosine kinase inhibitors represent the most frequent subsequent therapy in Spain.
The findings emphasize the clinical importance of preserving a patient’s functional status throughout the course of the disease. Maintaining functional capacity enables clinicians to administer subsequent lines of therapy that can offer meaningful clinical benefits.
Patient Advocates and Disease Burden Statistics
Elena Arcega, president of the Spanish Liver Federation, highlighted that patient participation in tracking registries helps improve care standards for future diagnoses, noting that research remains vital for advancing liver cancer care equitably. Coinciding with World Liver Cancer Day, TTD specialists emphasized the ongoing necessity of early diagnosis, multidisciplinary care, and biomarker identification.
According to figures from the Spanish Society of Medical Oncology, liver cancer diagnoses total approximately 7,000 cases annually in Spain. The five-year survival rate remains limited to approximately two in ten patients following initial detection.
Frequently Asked Questions About the RETUD Registry
What specific data does the RETUD registry collect from patients?
The RETUD registry compiles real-world clinical data from more than 800 patients in Spain, tracking treatment responses, survival metrics, and baseline liver function factors associated with hepatocellular carcinoma.
Which medical organizations presented findings from the registry?
Specialists from the Digestive Tumors Treatment Group presented data at the European Society for Medical Oncology Gastrointestinal Cancers Congress and the Spanish Society of Medical Oncology meeting.
How many new liver cancer cases are diagnosed annually in Spain?
The Spanish Society of Medical Oncology reports that liver cancer affects roughly 7,000 people each year in Spain, maintaining a five-year survival rate of about twenty percent.
Worth a look